Free tool
FAERS Monitor: Evista
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020815 or its brand name (Evista, Raloxifene Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
14,534
Serious
8,238
57% of reports
Hospitalization
3,468
Death reported
560
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- nausea777
- fall772
- drug ineffective751
- pain in extremity717
- pain686
- arthralgia637
- dizziness615
- muscle spasms588
- fatigue565
- headache557
- body height decreased532
- back pain470
- diarrhoea468
- bone density decreased456
- dyspnoea453
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,125 |
| 2005 | 990 |
| 2006 | 855 |
| 2007 | 715 |
| 2008 | 758 |
| 2009 | 743 |
| 2010 | 793 |
| 2011 | 621 |
| 2012 | 757 |
| 2013 | 530 |
| 2014 | 554 |
| 2015 | 3,688 |
| 2016 | 471 |
| 2017 | 429 |
| 2018 | 325 |
| 2019 | 291 |
| 2020 | 205 |
| 2021 | 165 |
| 2022 | 145 |
| 2023 | 113 |
| 2024 | 99 |
| 2025 | 96 |
| 2026 | 65 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,625 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| body height decreasedSignal | 532 | 75.7 | 69.5 | 37,220 |
| bone density decreasedSignal | 456 | 21.4 | 19.5 | 8,712 |
| muscle spasmsSignal | 588 | 4.6 | 4.3 | 1,689 |
| pain in extremitySignal | 717 | 3.5 | 3.3 | 1,311 |
| fallSignal | 772 | 3.4 | 3.1 | 1,296 |
| back painSignal | 470 | 2.9 | 2.7 | 602 |
| arthralgiaSignal | 637 | 2.2 | 2.1 | 433 |
| dizziness | 615 | 1.8 | 1.7 | 217 |
| pain | 686 | 1.6 | 1.5 | 165 |
| nausea | 777 | 1.4 | 1.3 | 100 |
| headache | 557 | 1.3 | 1.2 | 36 |
| dyspnoea | 453 | 1.2 | 1.1 | 10 |
| fatigue | 565 | 1.1 | 1.0 | 1 |
| diarrhoea | 468 | 1.0 | 1.0 | 1 |
| drug ineffective | 751 | 0.8 | 0.8 | 30 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.